R&D/ Views & Analysis/ Views and analysis 2018 in review: Alzheimer’s falters while oncology shines George Underwood 2018 in review, AI, Alzheimer's Research, CRISPR 0 Comment Going into 2018 you might have expected this to be the year of Alzheimer’s drugs, with several promising Share X 2018 in review: Alzheimer’s falters while oncology shines https://pharmaphorum.com/r-d/views-analysis-r-d/2018-review-alzheimers-research-oncology/
Digital/ Views & Analysis/ Views and analysis 2018 in review: AI on the rise in digital pharma Richard Staines 2018 in review, AI, digital, Nokia 0 Comment Digital technology is playing an increasingly important role in healthcare, and in the pharma industry as it searches Share X 2018 in review: AI on the rise in digital pharma https://pharmaphorum.com/views-analysis-digital/2018-digital-review-ai-on-the-rise-in-pharma/
Sales and Marketing/ Views & Analysis/ Views and analysis 2018 in review: Humira biosimilars arrive in Europe Dominic Tyer 2018 in review, biosimilars, Humira 0 Comment The emergence this year of Humira biosimilars in Europe followed a period of sustained momentum around the cheaper Share X 2018 in review: Humira biosimilars arrive in Europe https://pharmaphorum.com/views-analysis-sales-marketing/2018-review-humira-biosimilars-europe/
Oncology/ Views & Analysis/ Views and analysis 2018 in review: Merck & Co sets new standards in oncology, CAR-Ts hit EU market Richard Staines 2018 in review, CAR T, Merck & Co 0 Comment Oncology drugs are developing at a fast pace, but 2018 was the year when immune-oncology set new standards Share X 2018 in review: Merck & Co sets new standards in oncology, CAR-Ts hit EU market https://pharmaphorum.com/views-analysis-oncology/2018-in-review-merck-co-sets-new-standards-in-oncology-car-ts-hit-eu-market/
Market Access/ Views & Analysis/ Views and analysis 2018 in review: Governments start taking access seriously George Underwood 2018 in review, market access, pricing 0 Comment Market access has become a key focus for governments across the globe in 2018 – though as ever Share X 2018 in review: Governments start taking access seriously https://pharmaphorum.com/views-analysis-market-access/2018-in-review-governments-start-taking-access-seriously/
Patients/ Views & Analysis/ Views and analysis 2018 in review: How patient centricity led to new drugs that tackle unmet need Amanda Barrell 2018 in review, patient centricity 0 Comment The trend for working with patients, advocacy groups and appraisal authorities has yielded potentially life-changing results for patient Share X 2018 in review: How patient centricity led to new drugs that tackle unmet need https://pharmaphorum.com/views-analysis-patients/2018-in-review-how-patient-centricity-led-to-new-drugs-that-tackle-unmet-need/
